AtriCure, Inc. (NASDAQ: ATRC) reported Q3 EPS of ($0.02), $0.15 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $26.7 million versus the consensus estimate of $25.6 million.

“We had a strong third quarter with momentum across all of our product lines in both the U.S. and internationally. We continue to see increasing physician interest in managing the left atrial appendage and treating challenging Afib conditions,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “We see a tremendous amount of untapped potential in our markets, and thus our plans remain focused on growth and successfully expanding the Afib market through improved patient outcomes, training and education.”

“We are continuing to execute on our clinical trials, and we are pleased to have recently announced two major milestones toward delivering data to prove the benefit of our innovative products to patients. First, we completed enrollment in the ABLATE Post Approval Study (PAS) in the third quarter. Secondly, we recently received approval from the FDA to begin our Dual Epicardial and Endocardial Procedure (DEEP) clinical trial. This is the first study where cardiac surgeons and electrophysiologists will be working as a team to establish a standard of care for patients presenting with persistent or long-standing persistent Afib, a significant risk factor for stroke,” Mr. Carrel continued.

For earnings history and earnings-related data on AtriCure, Inc. (ATRC) click here.